Comparison of Efficacy of Bromfenac Sodium 0.1% Ophthalmic Solution and Fluorometholone 0.02% Ophthalmic Suspension for the Treatment of Allergic Conjunctivitis
- 1 June 2009
- journal article
- research article
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 25 (3) , 265-270
Abstract
Aims: Bromfenac sodium (BF) 0.1% was compared with fluorometholone (FML) 0.02% for the treatment of seasonal allergic conjunctivitis when concomitantly used with disodium cromoglycate (DSCG) 2.0%. Methods: Eighty-six patients with seasonal allergic conjunctivitis were treated with DSCG four times a day, and BF was concomitantly administered twice a day in one eye and FML was administered four times a day in the contralateral eye for 1 week. Ocular signs were scored on a four-graded severity. Patients recorded symptoms using visual analog scale. Patients were asked which concomitant treatment was more suitable for them and scored global evaluation. Results: All subjective symptom scores were decreased in both concomitant treatment groups compared with baseline (P < 0.05). Objective signs were significantly improved with the concomitant use of BF or FML with DSCG (P < 0.05). Neither symptoms nor signs differed significantly between the concomitant use of BF and FML. Fifteen patients selected BF and 29 patients selected FML as the more preferred concomitant eye drops, 42 patients judged no difference in efficacy between the groups. No significant difference was observed in patient’s global evaluation between the groups. Conclusions: Bromfenac sodium for allergic conjunctivitis was effective, with efficacy equivalent to that of FML when used with DSCG.Keywords
This publication has 12 references indexed in Scilit:
- Demographic aspects of allergic ocular diseases and evaluation of new criteria for clinical assessment of ocular allergyGraefe's Archive for Clinical and Experimental Ophthalmology, 2007
- Comparison of 0.1% Bromfenac Sodium and 0.1% Pemirolast Potassium for the Treatment of Allergic ConjunctivitisJapanese Journal of Ophthalmology, 2004
- Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitisActa Ophthalmologica Scandinavica, 2003
- Olopatadine inhibits TNFα release from human conjunctival mast cellsAnnals of Allergy, Asthma & Immunology, 2000
- Tumour necrosis factor alpha (TNFα) in tears of atopic patients after conjunctival allergen challengeClinical & Experimental Allergy, 1999
- A Multicenter Comparison of the Ocular Efficacy and Safety of Diclofenac 0.1% Solution with that of Ketorolac 0.5% Solution in Patients with Acute Seasonal Allergic ConjunctivitisJournal of Ocular Pharmacology and Therapeutics, 1998
- Chemokine Production in Conjunctival Epithelial Cells1998
- Inflammatory mediator release on conjunctival provocation of allergic subjects with allergenJournal of Allergy and Clinical Immunology, 1990
- Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogsJournal of Medicinal Chemistry, 1984
- Prostaglandin and histamine release from stimulated rat peritoneal mast cellsInflammation Research, 1984